You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
主要藥股升3%-8% 藥明生物、康希諾及百濟神州跑贏
阿思達克 03-10 12:13
醫藥板塊今天普遍跑贏大市。藍籌石藥集團(01093.HK)簽訂腫瘤產品授權商業化協議,該股今早重越牛熊線(8.66元),最高見9.24元為去年10月以來最高,半日收8.8元,回升5.8%。藍籌藥明生物(02269.HK)獲大和重申「買入」評級看135元及視為行業首選,認為近期股價過度調整是趁低吸納機會,該股繼昨天跌77.7元為去年12月中旬以來最低獲承接倒升後,今天高見89.2元,半日收88.1元,續升近6%。中生製藥(01177.HK)重越20天線(8.11元),半日收8.26元,續彈3%。

日前獲瑞銀給予「買入」評級分別升價至132.9元及109.7元的信達生物(01801.HK)及君實生物(01877.HK)股價曾分別重越百天線(73.66元)及50天線(73.3元),最高見75元及74.55元,半日收73.6元及73元,分別回升4.5%及續升4%,前者結束六連跌。獲瑞銀升價至21.4元的諾誠健華(09969.HK)昨天下跌守穩50天線後,今天股價扭四連跌,半日收17.56元,回升5.3%。

康希諾生物-B(06185.HK)Ad5-nCoV疫苗已申請在俄羅斯註冊,該股扭兩連跌,最高見283元,暫受制50天線(288元),半日收280.8元,回升6.2%。百濟神州(06160.HK)連升兩天,今天股價一舉重越百天線及10天線(178.6元及184.7元),最高見193.4元,半日收187.5元,續升7.8%。

藥明康德(02359.HK)繼昨天跌近三個月低位獲承接倒升後,今早股價高見150.6元(暫受制百天線151.7元),半日收148.7元,續升5.8%。聯邦制藥(03933.HK)重越50天、10天及20天線(5.73-5.86元),最高見5.93元,半日收5.87元,續升5.8%。四環醫藥(00460.HK)高見2.32元,半日收2.28元,續彈5.6%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account